GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Replimune Group Inc.
Replimune is a biotech company developing cancer immunotherapy drugs. Its stock price is highly volatile and driven by news about clinical trials. The chart reflects investor hopes for the development of a new generation of cancer drugs.
Share prices of companies in the market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapies for cancer treatment. Its drugs are designed to activate the immune system to fight tumors. We classify this group as "Immuno-oncology." The graph below shows the overall dynamics of this cutting-edge field of medicine.
Broad Market Index - GURU.Markets
Replimune is an oncology company developing a new class of immunotherapeutic drugs based on oncolytic viruses. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors are valuing this breakthrough technology.
Change in the price of a company, segment, and market as a whole per day
REPL - Daily change in the company's share price Replimune Group Inc.
The daily price change of Replimune, an oncology company focused on immunotherapy, reflects the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator is the basis for analysis of the cancer drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Replimune Group, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with REPL's performance, which hinges on the results of clinical trials for its oncolytic immunotherapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Replimune is a biopharmaceutical company developing oncolytic immunotherapy for the treatment of cancer. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and dynamics of Replimune stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Replimune Group Inc.
Replimune Group's year-over-year performance is driven by a new class of anti-cancer therapy—oncolytic viruses. Its market capitalization over the next 12 months is entirely dependent on clinical trial data. Positive results from combining its viral therapy with traditional immune drugs could lead to explosive growth, opening up a huge market.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Replimune Group, Inc. is a late-stage biotech developing oncolytic immunotherapy. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this cutting-edge area of cancer treatment.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Replimune is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cancer immunotherapy trials. The company's stock chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Replimune Group Inc.
Replimune, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its clinical trials for its oncolytic immunotherapy, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Replimune is developing a new generation of oncolytic immunotherapies—viruses engineered to destroy cancer cells and stimulate the immune system. This represents the cutting edge of cancer treatment. The chart below shows the dynamics of the biotech sector, where investors are evaluating the potential of breakthrough oncology platforms.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Replimune Group is a biotech company developing oncolytic immunotherapies. Its shares are dominated by news about clinical trials. The success or failure of trials can cause sharp price movements, completely ignoring overall market trends. The chart clearly demonstrates this disconnect from the overall economic backdrop.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Replimune Group Inc.
Replimune Group develops oncolytic immunotherapies for cancer treatment. Its weekly stock price is extremely volatile and directly depends on the publication of clinical trial data. This chart tells the story of how investor hopes for a new cancer treatment drive the company's value.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Replimune, like the entire oncology immunotherapy sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks, which impact investor interest in the entire field. The chart shows how the company follows this general biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Replimune Group is a biotech company in the immuno-oncology field, where news is king. This chart allows us to separate the unique investor reaction to the company's scientific data from the overall market sentiment. How does its story stand out from the crowd and defy macro noise?
Market capitalization of the company, segment and market as a whole
REPL - Market capitalization of the company Replimune Group Inc.
The Replimune Group chart is a visualization of the hopes in cancer immunotherapy. Its market capitalization, like that of many biotech companies, reflects not current profits, but investors' faith in the potential of its oncolytic viruses to fight tumors. This is the scientific expectations curve.
REPL - Share of the company's market capitalization Replimune Group Inc. within the market segment - Oncology immuno-therapy
Replimune Group is a pioneer in the development of next-generation oncolytic immunotherapies. Its market share reflects the potential of its platform for creating viruses that selectively destroy cancer cells and stimulate the immune response.
Market capitalization of the market segment - Oncology immuno-therapy
Replimune Group is developing oncolytic immunotherapy. How big is the overall cancer arena? The chart below shows the pulse of this biotech sector. Its growth and volatility reflect the enormous investment and hopes associated with the discovery of revolutionary cancer treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Replimune Group chart shows how the market is pricing the next generation of cancer immunotherapy. The company's market cap is based on the potential of its oncolytic virus platform. The chart's dynamics visualize the hopes and risks associated with clinical trials that could offer new treatment options for cancer patients.
Book value capitalization of the company, segment and market as a whole
REPL - Book value capitalization of the company Replimune Group Inc.
For Replimune Group, which develops oncolytic immunotherapeutic drugs, book value is its physical foundation: production facilities, laboratories, and significant financial reserves for clinical trials. The chart below shows how the company built this physical foundation to fight cancer.
REPL - Share of the company's book capitalization Replimune Group Inc. within the market segment - Oncology immuno-therapy
Replimune Group fights cancer, and its main tangible asset is its own state-of-the-art manufacturing facility for oncolytic immunotherapeutic drugs. This facility is the physical heart of its innovative platform. The chart shows the company's control over this unique manufacturing infrastructure in its field.
Market segment balance sheet capitalization - Oncology immuno-therapy
Replimune Group develops oncolytic viruses. The pharmaceutical industry, as the chart shows, is capital-intensive. Replimune is a prime example. Its business requires the construction of its own, highly complex and expensive factories to produce its drugs.
Book value of all companies included in the broad market index - GURU.Markets
Replimune's scientific breakthroughs require a substantial financial base: cutting-edge laboratories and production facilities under construction for the creation of oncolytic viruses. The chart below visualizes how the company is building its physical foundation for the fight against cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Replimune Group Inc.
Replimune is a biotech company with laboratories. Its market valuation is based on pure faith in their oncolytic virus platform. The chart below visualizes the rise and fall of investor hopes for their scientific breakthrough.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of immuno-oncology drugs. Like many clinical-stage biotechs, its valuation is based on future potential. The chart shows a significant excess of market capitalization over assets, reflecting investor confidence in its scientific approach.
Market to book capitalization ratio for the market as a whole
Replimune Group is developing a new generation of oncolytic viruses to combat cancer. Its current valuation, compared to the average on this chart, is unrelated to its assets. It is a pure bet by investors on the scientific success of its platform and the potential to create a new class of anti-cancer drugs, where the risk and potential reward are very high.
Debts of the company, segment and market as a whole
REPL - Company debts Replimune Group Inc.
Replimune Group is developing a new generation of oncolytic immunotherapies. This chart reflects the financial reality of a clinical-stage biotech company. It is raising significant equity capital to finance lengthy and expensive clinical trials of its drug candidates, betting on a future scientific breakthrough.
Market segment debts - Oncology immuno-therapy
Replimune Group is a clinical-stage biotechnology company developing a new generation of oncolytic viruses for cancer treatment. Funding expensive clinical trials is its primary goal. This chart shows how the company's debt burden reflects its capital needs to advance its innovative immunotherapy platform through regulatory approvals.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Replimune Group Inc.
Replimune Group is a biotech company developing immuno-oncology drugs. Drug development requires significant and risky investments. This chart reflects the extent to which the company uses debt financing to conduct expensive clinical trials. It demonstrates its financial resilience during the long journey to approval and commercialization.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapies. This chart shows the debt burden in the biotech sector. For companies in clinical trials, it is a critical indicator of their ability to fund expensive research that could lead to breakthroughs in cancer treatment.
Debt to book value of all companies in the market
Replimune Group is a clinical-stage biopharmaceutical company focused on oncology. It doesn't yet have stable revenue, and its development is financed by equity. This chart of total market debt helps assess the investment climate. Is it easy for companies of this type to attract debt financing for expensive research?
P/E of the company, segment and market as a whole
P/E - Replimune Group Inc.
Replimune Group is developing a new generation of oncolytic immunotherapeutic drugs that use modified viruses to destroy cancer cells. This graph reflects the high, yet risky, expectations of investors in cutting-edge science. Its dynamics depend entirely on the results of clinical trials and confidence in the potential of this technology.
P/E of the market segment - Oncology immuno-therapy
Replimune Group is a biotech company at the forefront of immuno-oncology. It is developing a new generation of oncolytic viruses engineered to attack cancer cells and stimulate the immune response. This chart shows the average valuation for the immuno-oncology sector, reflecting investor expectations for a breakthrough in cancer treatment.
P/E of the market as a whole
Replimune Group is a biotech company developing oncolytic viruses—a new class of cancer therapy. Its valuation is a pure bet on the success of this innovative technology. It is in no way tied to the general economic cycles illustrated by this chart. Its fate is decided in clinics and depends on whether its viruses can effectively fight tumors.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Replimune Group Inc.
Replimune Group is a biotech company developing oncolytic immunotherapies—modified viruses to fight cancer. This chart reflects the high expectations for its cutting-edge scientific platform. The company's valuation is based not on current revenue, but on investors' confidence in the success of clinical trials and the future commercial potential of its drugs.
%20P%2FE%20Replimune%20Group%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Replimune-Group-Inc.&v=1772513568847 "Chart of the company's future (projected) P/E Replimune Group Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Replimune Group is developing a new class of oncolytic immunotherapeutic drugs for the treatment of cancer. Like many development-stage biotech companies, its valuation is based on future potential. This chart reflects investor confidence in its scientific approach. Comparing forecasts with the sector shows how highly the market perceives the success of its drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772513568870 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Replimune Group is developing next-generation immuno-oncology drugs. This is a high-risk area of biotechnology, where the potential for success is enormous. This overall risk appetite directly impacts Replimune's ability to raise capital for the costly clinical trials on which its future depends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513568969 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Replimune Group Inc.
Replimune Group, Inc. is a biotechnology company developing oncolytic immunotherapies—viral-based drugs for the treatment of cancer. The company is currently in clinical trials. This schedule reflects significant R&D expenditures, and future profits depend on the successful registration and commercialization of its drugs.
Profit of companies in the market segment - Oncology immuno-therapy
Replimune Group is at the forefront of medicine, developing oncolytic immunotherapies—drugs that use viruses to fight cancer. This is a high-risk, high-potential field. The profitability chart for this biotech segment shows how research breakthroughs and drug approvals influence investor sentiment and financial flows across the industry.
Overall market profit
Replimune Group develops oncolytic immunotherapies, a new class of cancer treatments. The company is at the forefront of biotech innovation. Its potential success could not only save lives but also create enormous shareholder value, demonstrating how scientific breakthroughs are becoming a powerful growth engine in the healthcare sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Replimune Group Inc.
Replimune Group is developing a new class of oncolytic immunotherapies for the treatment of cancer. This graph reflects high, yet speculative, expectations for its clinical development. Future revenue is entirely dependent on successful research results and subsequent regulatory approval.
%20profit%20of%20the%20company%20Replimune%20Group%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Replimune-Group-Inc.&v=1772513569065 "Graph of future (projected) profit of the company Replimune Group Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapies for cancer treatment. This chart shows the expected revenue growth rate for the biotech sector. It provides an opportunity to assess investor expectations for the company's breakthrough cancer treatments within the context of the entire innovation industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772513569082 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
The trajectory on this chart illustrates expectations for a biotech company developing oncolytic immunotherapy. Replimune Group's profit forecast depends on the results of its clinical trials and subsequent regulatory approval. This is a classic biotech story, where expectations are based on scientific potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513569104 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Replimune Group Inc.
Replimune, a clinical-stage biopharmaceutical company, does not yet have significant revenue from its products. This chart shows a valuation based on the expected future success of its oncology drugs. This represents investors' faith in the scientific platform and the potential for commercial success.
P/S market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapies for the treatment of cancer. Being in the clinical stage, the company does not yet have stable sales revenue. This chart reflects the industry average valuation based on revenue expectations for breakthrough drugs, allowing one to assess Replimune's potential compared to other biotech companies.
P/S of the market as a whole
Replimune Group is a biotech company developing a new class of oncolytic immunotherapies for the treatment of cancer. The company does not yet have stable sales revenue. This chart, showing the average market revenue estimate for Replimune, emphasizes that its valuation is based on expectations from clinical trials and the potential of its scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Replimune Group Inc.
Replimune Group is a biotechnology company developing oncolytic immunotherapies, a new class of cancer treatments. The company does not yet have any commercial products. This chart reflects investor expectations for the future. It shows the market's assessment of the likelihood of clinical trial success and subsequent approval of its drugs.
%20P%2FS%20Replimune%20Group%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Replimune-Group-Inc.&v=1772513569192 "The graph of the company's future (projected) P/S Replimune Group Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapeutics for the treatment of cancer. This chart compares market expectations for its future revenue with other oncology companies. This valuation reflects investor confidence in its platform and the potential of its drug candidates to stimulate the immune system against tumors.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772513569221 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Replimune Group is a biotechnology company developing oncolytic immunotherapies, a new class of drugs to fight cancer. Its future depends on the success of clinical trials. Replimune's potential to create breakthrough treatments is part of the overall optimism surrounding pharmaceutical innovation, reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513569238 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Replimune Group Inc.
Replimune Group is developing a new class of oncolytic immunotherapies for the treatment of cancer. As a clinical-stage biotech company, it may not have stable sales revenue. This chart shows revenue if the drugs are commercialized or if payments are received under partnership agreements.
Sales of companies in the market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapeutics that use modified viruses to destroy cancer cells and stimulate the immune response. This chart shows overall pharmaceutical sales, demonstrating the rapidly growing interest and investment in advanced cancer treatments, where Replimune is an innovator.
Overall market sales
Replimune Group is a biotech company developing a new generation of virus-based immuno-oncology drugs for the treatment of cancer. This overall economic activity chart for Replimune is important from the perspective of investments. A strong economy ensures an influx of venture capital into the biotech sector, which is critical for funding long-term clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Replimune Group Inc.
Replimune Group is developing a new generation of oncolytic viruses for cancer treatment. The company is in the clinical stage, and its future revenue depends on successful trial results and subsequent drug approval. This chart reflects analyst expectations regarding the scientific potential of Replimune's platform and the likelihood of commercial success.
%20sales%20of%20the%20company%20Replimune%20Group%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Replimune-Group-Inc.&v=1772513569355 "Schedule of future (projected) sales of the company Replimune Group Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Replimune Group develops oncolytic immunotherapies for the treatment of cancer. This chart shows projected revenues for the entire biotech sector. It reflects general expectations for investment in oncology research, but for Replimune, the success of clinical trials for its innovative drugs is key.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772513569372 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Replimune Group is a biotechnology company developing oncolytic immunotherapies for the treatment of cancer. Its valuation depends on the success of clinical trials and future commercial prospects. This graph, reflecting the overall economic situation, influences the investment climate in the biotechnology sector. During periods of growth, investors are more inclined to fund risky but promising developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513569393 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Replimune Group Inc.
Replimune Group is a biotech company developing immuno-oncology drugs. The chart for such a company in the clinical development stage reflects its financial discipline. This metric demonstrates how the company manages the enormous costs of developing and testing its drug candidates, which are the key to future profitability.
Market segment marginality - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapeutics for cancer treatment. It is at the cutting edge of oncology. This chart reflects the company's operational structure at the clinical trial stage. It demonstrates its high investment in research compared to other biotech companies striving to create breakthrough cancer treatments.
Market marginality as a whole
Replimune Group is developing a new generation of oncolytic immunotherapies for the treatment of cancer. The company's future profitability depends on the success of its clinical programs and regulatory approvals. This total market profitability chart serves as a contrast to the biotech industry, where value is created by scientific breakthroughs and addressing unmet medical needs, not by macroeconomics.
Employees in the company, segment and market as a whole
Number of employees in the company Replimune Group Inc.
Replimune Group is a biotechnology company developing a new generation of oncolytic immunotherapies for cancer treatment. This chart shows the growing team of scientists and clinicians. This increase directly reflects progress in clinical trials and investments in expanding the platform for developing new drug candidates.
Share of the company's employees Replimune Group Inc. within the market segment - Oncology immuno-therapy
This graph reflects Replimune Group's cutting-edge approach to fighting cancer. The company's oncology team is focused on developing a new class of immunotherapeutic drugs—oncolytic viruses. This team of scientists "programs" viruses to selectively destroy cancer cells and stimulate the patient's immune system.
Number of employees in the market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapeutic drugs that "tune" the immune system to fight cancer. This is at the cutting edge of science. This graph illustrates how science-intensive oncology has become, with companies like Replimune creating a demand for world-class immunologists, virologists, and geneticists.
Number of employees in the market as a whole
Replimune Group, Inc. develops oncolytic immunotherapies. Its value is created in the laboratory and clinical settings, not in the labor market, as reflected in this chart. The company's success depends on its ability to create a new generation of cancer drugs, a fundamental value independent of economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Replimune Group Inc. (REPL)
Replimune Group is developing a new generation of oncolytic immunotherapeutics. This chart shows the biotech company's valuation at the clinical stage. The astronomical market capitalization per scientist reflects not current revenue, but rather the enormous investor expectations for the potential success of its innovative cancer treatment platform.
%20of%20the%20company%20Replimune%20Group%20Inc.%20(REPL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Replimune-Group-Inc.-REPL&v=1772513569658 "Chart of market capitalization per employee (in thousands of dollars) of the company Replimune Group Inc. (REPL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Replimune Group is developing a new generation of oncolytic immunotherapeutic drugs. In biopharmaceuticals, market capitalization per employee reflects the market's assessment of scientific potential. This chart shows the value investors are placing on the company's developments, which could change approaches to cancer treatment.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772513569682 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Replimune Group, Inc. is a clinical-stage biotech company developing oncolytic immunotherapy. This chart shows a very high valuation per employee. This reflects not current revenue but investor expectations for the success of its cancer drugs. The company's value is a valuation of its science and intellectual property.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513569701 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Replimune Group Inc. (REPL)
Replimune Group is a clinical-stage biotech company developing oncolytic immunotherapies (viruses "programmed" to kill cancer cells). The company has no commercial profit. This chart reflects the net loss (R&D and testing costs) per scientist and employee working on the next breakthrough.
%20Chart%20Replimune%20Group%20Inc.%20(REPL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Replimune-Group-Inc.-REPL&v=1772513569733 "Company Profit Per Employee (in thousands of dollars) Chart Replimune Group Inc. (REPL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Replimune Group is a biotech company developing oncolytic immunotherapies (drugs that use viruses to fight cancer). It's at the cutting edge of science. There's no profit at the clinical trial stage. This chart shows the company's cash burn per employee. It serves as a benchmark for assessing how intensively the company invests in R&D per scientist compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772513569754 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Replimune Group (REPL) is a biotech company developing oncolytic immunotherapies (drugs that use viruses to attack cancer cells). The company is in the clinical stage. This graph likely shows a significant loss per employee. It reflects the high cost of R&D: each scientist and physician involved in research requires a huge investment that has not yet generated revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513569811 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Replimune Group Inc. (REPL)
Replimune Group is developing a new generation of oncolytic immunotherapeutics for the treatment of cancer. This chart reflects the biotech company's clinical-stage activities. Revenue per employee is minimal and dependent on partnerships, with the primary value generated through successful clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Replimune-Group-Inc.-REPL&v=1772513569896 "Sales chart per company employee Replimune Group Inc. (REPL)")
Sales per employee in the market segment - Oncology immuno-therapy
Replimune Group is a biotech company developing oncolytic viruses for cancer immunotherapy. This chart shows the average revenue per employee in the segment. For a clinical-stage company, revenue, if any, comes from partnerships. The chart shows the average productivity for the sector, which serves as a benchmark for assessing Replimune's potential.
Sales per employee for the market as a whole
Replimune is a clinical-stage biotechnology company developing oncolytic viruses—a new class of cancer immunotherapy. The company currently has no commercial products and, consequently, no sales revenue. This revenue will be zero, as their staff (scientists) is entirely focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Replimune Group Inc. (REPL)
Replimune Group is a biotech company developing oncolytic viruses (cancer immunotherapy). This is a cutting-edge but risky field. The bearish sentiment seen in this chart reflects skepticism about the success of clinical trials. Bears are betting that the technology will prove ineffective or unsafe, which is typical of biotech R&D.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Replimune-Group-Inc.-REPL&v=1772513570045 "Short Shares Chart for the Company Replimune Group Inc. (REPL)")
Shares shorted by market segment - Oncology immuno-therapy
Replimune Group is a biotech company developing a new generation of oncolytic viruses—"trained" viruses that attack cancer cells. They are at the forefront of immunotherapy. This chart reflects the overall sentiment in the sector. It reflects the high level of investor skepticism toward the entire industry, with investors anticipating R&D setbacks or funding challenges for risky developments.
Shares shorted by the overall market
Replimune Group is a clinical-stage biotech company working in immuno-oncology. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable, speculative ventures like REPL, fearing they'll run out of money.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Replimune Group Inc. (REPL)
Replimune (REPL) is a biotech company developing oncolytic viruses—smart viruses programmed to destroy cancer cells and stimulate the immune system. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to delays or setbacks in R&D.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Replimune-Group-Inc.-REPL&v=1772513570206 "RSI 14 indicator chart for the company's stock Replimune Group Inc. (REPL)")
RSI 14 Market Segment - Oncology immuno-therapy
Replimune (REPL) is a biotech company developing a new generation of oncolytic immunotherapeutics. These drugs use weaponized viruses to attack cancer cells. This chart measures overall sentiment in the Immuno-Oncology sector. It helps distinguish Replimune's successful trials from overall overheating or overselling in the biotech sector.
RSI 14 for the overall market
Replimune (REPL) is a biotech company. Like everything in its sector, it's critically dependent on this price chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast REPL (Replimune Group Inc.)
Replimune (REPL) is a clinical-stage biotech company specializing in oncolytic immunotherapy. It develops weaponized viruses that are injected into tumors to destroy them and stimulate an immune response. This chart shows the average analyst forecast, reflecting their assessment of clinical trial data and the potential of this platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-REPL-Replimune-Group-Inc.&v=1772513570261 "A chart showing analyst consensus forecasts for the expected stock price. REPL (Replimune Group Inc.)")
The difference between the consensus estimate and the actual stock price REPL (Replimune Group Inc.)
Replimune (REPL) is a biotech company developing a new generation of oncolytic viruses—viruses programmed to seek out and destroy cancer cells. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their immunotherapy platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-REPL-Replimune-Group-Inc.&v=1772513570280 "A chart showing the difference between the consensus forecast and the actual stock price. REPL (Replimune Group Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Replimune is a biotech company operating at the cutting edge of science. It develops oncolytic viruses—smart viruses programmed to seek out and destroy cancer cells. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe this complex R&D platform is successful or whether they consider it too risky.
Analysts' consensus forecast for the overall market share price
Replimune Group is a biotech company specializing in the development of "oncolytic" viruses—viruses programmed to destroy cancer cells and stimulate the immune system. This chart shows the overall risk appetite. For Replimune, which operates in a cutting-edge but high-risk field, overall market optimism is critical to funding long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Replimune Group Inc.
Replimune (REPL) is a clinical-stage biotech company at the forefront of oncology. They develop oncolytic viruses—intelligent viruses programmed to infect and kill only cancer cells. This chart represents a high-risk R&D bet. Its valuation reflects the market's faith in their revolutionary platform and their clinical trial data.
AKIMA Market Segment Index - Oncology immuno-therapy
Replimune (REPL) is a clinical-stage biotech and a pioneer in oncolytic viruses. The company is developing a new generation of smart viruses designed to destroy cancer cells and stimulate the immune system. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (R&D) platform (REPL) differentiate it from the average pharma company?
The AKIM Index for the overall market
Replimune is a biotech company developing oncolytic immunotherapies (viruses that kill cancer). It's at the forefront of the fight against cancer. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such innovative but unprofitable companies.
